OssDsign AB September 26th, 2023 announced a strategic shift to focus its operations on the orthobiologics business in the U.S. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst.
All activities pertaining to the company’s patient-specific cranial implant business will be discontinued in a responsible manner by the end of December 2023.
This website uses cookies to improve your user experience, to provide a basis for improvement and further development of the website and to be able to direct more relevant offers to you.
Feel free to read ours privacy policy. If you agree to our use, choose Accept all. If you want to change your choice afterwards, you will find that option at the bottom of the page.
